首页> 外文期刊>European Journal of Pharmacology: An International Journal >The cytoprotective role of a low-molecular-weight heparin fragment studied in an experimental model of glomerulotoxicity.
【24h】

The cytoprotective role of a low-molecular-weight heparin fragment studied in an experimental model of glomerulotoxicity.

机译:在肾小球毒性实验模型中研究了低分子量肝素片段的细胞保护作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Abnormal glomerular glycosaminoglycan metabolism is involved in the onset of the morphological and functional aberrations of glomerulopathies. In the present study, a heparin derivative, low-molecular-weight heparin, was tested for its ability to afford renoprotection in an established model of experimental glomerulopathy. Two groups of male albino rats of the Wistar strain (140 +/- 10 g) received a single intravenous injection of adriamycin (7.5 mg/kg) to induce glomerulopathy, and one of them received low-molecular-weight heparin (Certoparin Sodium, Troparin; 300 microg/day/rat s.c.) treatment, commencing on day 8, for a week. Urinary protein/creatinine ratio, serum albumin, urea, uric acid and creatinine clearance were evaluated. Renal cell injury was assessed in terms of renal tissue lactate dehydrogenase, aminotransferases (aspartate and alanine transaminases) and alkaline phosphatase activities, as well as renal antioxidant status (superoxide dismutase, catalase and glutathione peroxidase, reduced glutathione, vitamins E and C). The kidney tissue was subjected to histopathologic examination. Low-molecular-weight heparin significantly reduced proteinuria and improved creatinine clearance and serum albumin levels in the rats with glomerulopathy. The significant rise in serum uric acid in the rats with glomerulopathy was reversed by low-molecular-weight heparin. Altered tissue enzyme activities in response to injury, oxidative stress challenged renal antioxidant system and abnormal renal histology were observed in the untreated nephrotic rats, while low-molecular-weight heparin treatment protected the nephrotic rats against these changes. Thus, in this study, low-molecular-weight heparin was evaluated for its role in combating glomerular injury, on the basis of some salient biochemical parameters, oxidative injury indices and histologic picture. The ability of low-molecular-weight heparin to restore glomerular anatamo-functional features in this nephrotoxic condition illuminates its multi-faceted renoprotective role.
机译:肾小球糖胺聚糖代谢异常与肾小球病的形态和功能异常的发生有关。在本研究中,在已建立的实验性肾小球病模型中,测试了肝素衍生物低分子量肝素对肾脏的保护能力。两组Wistar品系(140 +/- 10 g)的雄性白化病大鼠接受单次静脉注射阿霉素(7.5 mg / kg)诱导肾小球病,其中一组接受低分子量肝素(Certoparin Sodium,肌钙蛋白; 300微克/天/大鼠sc)治疗,从第8天开始,持续一周。评估尿蛋白/肌酐比率,血清白蛋白,尿素,尿酸和肌酐清除率。根据肾组织乳酸脱氢酶,氨基转移酶(天冬氨酸和丙氨酸转氨酶)和碱性磷酸酶的活性,以及​​肾脏的抗氧化状态(超氧化物歧化酶,过氧化氢酶和谷胱甘肽过氧化物酶,还原型谷胱甘肽,维生素E和C)评估肾细胞损伤。对肾脏组织进行组织病理学检查。低分子量肝素可显着降低肾小球病大鼠的蛋白尿并改善肌酐清除率和血清白蛋白水平。低分子量肝素逆转了肾小球病大鼠血清尿酸的显着升高。在未经治疗的肾病大鼠中观察到了响应损伤,氧化应激挑战肾脏抗氧化系统和异常肾组织学而改变的组织酶活性,而低分子量肝素治疗可以保护肾病大鼠免受这些变化的影响。因此,在这项研究中,基于一些重要的生化参数,氧化损伤指数和组织学图像,评估了低分子量肝素在对抗肾小球损伤中的作用。在这种肾毒性情况下,低分子量肝素恢复肾小球无色素功能的能力阐明了其多方面的肾脏保护作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号